Production of deoxyribonucleoside triphosphate (dNTP) precursors for DNA synthesis is critical for cell proliferation and genomic integrity. Two biosynthetic pathways contribute to cellular dNTP pools: de novo synthesis and deoxyribonucleoside salvage. This application focuses on deoxycytidine kinase (DCK), a key enzyme in the salvage pathway. DCK has unique properties: it provides cells with all 4 dNTPs and is essential for the activation of nucleoside analog drugs used in cancer. We hypothesize that the enzymatic activity of DCK can be imaged by Positron Emission Tomography (PET) and that PET assays that measure DCK may allow stratification of cancer patients for treatment with nucleoside analog drugs. To test these hypotheses we propose a multidisciplinary project that combines genetic, molecular biology, biochemical and molecular imaging approaches to investigate the biological function of DCK and to develop PET probes to monitor its activity in vivo. This work leverages tools and reagents identified in the current ICMIC cycle;we developed [ [18] F]-1-(2'-deoxy-2'-fluoroarabinofuranosyl) cytosine ([ [18]F] FAC), a new DCK substrate PET probe, using a new approach to identify potential imaging agents. The team of proposed investigators has combined excellence in cancer biology, molecular biology, biochemistry, radiochemistry, preclinical and clinical molecular imaging. The strength of this collaboration is demonstrated by the fact that in the last 24 months we have taken a series of PET probes from extensive in vitro selection and evaluation to in vivo PET investigations in mice, and then to patients. This project will use all three ICMIC Specialized Resources.
In Specific Aim 1 we will develop a novel experimental model that allows conditional inactivation of the DCK gene in mice. The DCK deficient mice will be used to validate the tissue retention of [ [18]F] FAC as an accurate non-invasive measurement of DCK activity in vivo and to interpret the results of PET assays using DCK-specific probes.
In Specific Aim 2 we will design, synthesize and evaluate optimized [ [18]F] FAC probes.
Specific Aim 3 proposes the clinical translation of DCK-specific probes and the development of new molecular imaging approaches to predict tumor responses to DCK-dependent drugs.

Public Health Relevance

The scientific yield from this project should widen the utility of molecular imaging approaches and may lead to improved therapies for cancer, significantly impacting public health. Moreover, this project provides a path by which new non-invasive molecular imaging diagnostic probes and assays are discovered, developed and translated to the clinic to yield approaches for stratification of treatment options in cancer.

Agency
National Institute of Health (NIH)
Type
Specialized Center (P50)
Project #
5P50CA086306-15
Application #
8731102
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Jiao, Jing; Ishikawa, Tomo-O; Dumlao, Darren S et al. (2014) Targeted deletion and lipidomic analysis identify epithelial cell COX-2 as a major driver of chemically induced skin cancer. Mol Cancer Res 12:1677-88
Jiao, Jing; Mikulec, Carol; Ishikawa, Tomo-o et al. (2014) Cell-type-specific roles for COX-2 in UVB-induced skin cancer. Carcinogenesis 35:1310-9
Shurell, Elizabeth; Tran, Linh M; Nakashima, Jonathan et al. (2014) Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients. BMC Cancer 14:827
Mongini, Patricia K A; Kramer, Jill M; Ishikawa, Tomo-O et al. (2014) Candidate chromosome 1 disease susceptibility genes for Sjogren's syndrome xerostomia are narrowed by novel NOD.B10 congenic mice. Clin Immunol 153:79-90
Wilks, Moses Q; Knowles, Scott M; Wu, Anna M et al. (2014) Improved modeling of in vivo kinetics of slowly diffusing radiotracers for tumor imaging. J Nucl Med 55:1539-44
Schwarzenberg, Johannes; Czernin, Johannes; Cloughesy, Timothy F et al. (2014) Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res 20:3550-9
Wardak, Mirwais; Schiepers, Christiaan; Cloughesy, Timothy F et al. (2014) ¹?F-FLT ???and ¹?F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging 41:1199-209
Nathanson, David A; Armijo, Amanda L; Tom, Michelle et al. (2014) Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. J Exp Med 211:473-86
Hirata, Kenji; Kobayashi, Kentaro; Wong, Koon-Pong et al. (2014) A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS One 9:e105682
Escuin-Ordinas, Helena; Atefi, Mohammad; Fu, Yong et al. (2014) COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol Oncol 8:250-60

Showing the most recent 10 out of 184 publications